Innate Pharma to Present IPH4502

Innate Pharma will present clinical development findings for IPH4502, its investigational Nectin-4 antibody-drug conjugate (ADC), at an in-person and virtual event in London on November 18, 2026. The event will focus on Phase 1 dose-escalation data from the company’s clinical programme and the potential next steps for the experimental cancer treatment.

The Marseille-based biotechnology company said the event would take place at 11:00 a.m. Eastern Time, equivalent to 4:00 p.m. GMT, at the IET London, Savoy Place. Participants will also be able to join virtually, with a replay expected to be made available through the investor section of Innate Pharma’s website.

Professor Yohann Loriot, a medical oncologist and Professor of Medicine at Gustave Roussy, will join Innate Pharma’s management team to discuss the clinical findings. The programme will cover the safety profile, pharmacokinetics and preliminary antitumour activity observed in the Phase 1 dose-escalation study.

The discussion will also examine the treatment landscape and unmet medical needs in urothelial cancer, including bladder cancer. Professor Loriot will provide a clinical perspective, while company management will explain the scientific rationale behind IPH4502 and outline its planned clinical development.

A live question-and-answer session will follow the presentations.

Phase 1 study enrolled 76 patients

The November event follows the completion of enrolment in the dose-escalation portion of Innate Pharma’s IPH4502-101 Phase 1 study. The company announced in July 2026 that 76 patients had been enrolled across multiple solid tumour types in France and the United States.

In its July update, Innate Pharma reported that IPH4502 had shown a favourable safety profile to that point, with limited haematological toxicity. The company also reported preliminary antitumour activity, including objective responses in heavily pre-treated patients with urothelial carcinoma following treatment with enfortumab vedotin, as well as in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.

These observations were reported by the company during early clinical development. They do not establish the treatment’s effectiveness or confirm that it will provide a clinical benefit in larger patient populations.

The upcoming presentation is expected to provide further information from the completed dose-escalation dataset. The findings will be relevant to decisions about dose optimisation and the selection of tumour types for subsequent clinical evaluation.

The study is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of IPH4502 as a single-agent treatment in patients with advanced solid tumours known to express Nectin-4.

IPH4502 targets Nectin-4 in solid tumours

IPH4502 is an antibody-drug conjugate designed to deliver a cancer-killing payload to tumour cells expressing Nectin-4, a cell-surface protein found at elevated levels in several solid tumour types.

The investigational drug combines three principal components: a humanised antibody that binds to Nectin-4, a proprietary linker and an exatecan payload. Exatecan is a topoisomerase I inhibitor, a type of compound that interferes with the process cancer cells use to replicate their DNA.

The antibody component is designed to recognise Nectin-4 on tumour cells. The linker connects the antibody to the drug payload and is designed to remain stable in circulation while controlling the release of the active compound.

Innate Pharma says its proprietary linker is intended to slow the release of free exatecan into the bloodstream. The company believes this design could help address some limitations associated with other ADC technologies.

The payload also differentiates IPH4502 from enfortumab vedotin, a Nectin-4-targeting ADC that uses monomethyl auristatin E (MMAE). Innate Pharma’s approach uses exatecan and is designed to address potential resistance mechanisms, including those associated with multidrug resistance protein 1 (MDR1).

The company has also described the antibody’s binding site as distinct from the epitope targeted by enfortumab vedotin. In preclinical studies, IPH4502 demonstrated antitumour activity in models resistant to enfortumab vedotin and in tumours with low or heterogeneous Nectin-4 expression.

These preclinical findings provide the scientific rationale for the programme, but they do not establish that the same effects will occur in patients.

Development extends beyond urothelial cancer

Although the November event will include a discussion of urothelial cancer, Innate Pharma is evaluating IPH4502 in a broader range of advanced solid tumours known to express Nectin-4.

The Phase 1 programme includes patients with several tumour types, including urothelial carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, breast cancer, ovarian cancer, gastric cancer, oesophageal cancer and colorectal cancer.

This approach allows the company to investigate whether the treatment may have potential applications beyond its initial focus on urothelial cancer. However, the clinical programme remains at an early stage, and further studies will be needed to establish safety, identify appropriate doses and assess activity in individual tumour types.

The dose-escalation findings are expected to help guide the next stage of development. Dose optimisation is an important part of early oncology research because it helps investigators identify a dose and treatment schedule that can be evaluated in subsequent studies while considering both safety and potential antitumour activity.

The IPH4502-101 study is registered as NCT06781983. It is a first-in-human, open-label, multicentre Phase 1 trial in patients with advanced solid tumours known to express Nectin-4.

Clinical and scientific perspective at London event

Professor Yohann Loriot will provide an independent clinical perspective during the event, alongside Innate Pharma’s management team.

Loriot is a medical oncologist specialising in genitourinary cancers, particularly bladder cancer, at Gustave Roussy in France. He serves as Deputy Head of the Department of Therapeutic Innovation and Early Drug Development and coordinates the UNLOCK programme, which studies mechanisms of sensitivity and resistance to innovative cancer treatments.

His research focuses on the development of new therapeutic strategies and treatment resistance in solid tumours, particularly urothelial and prostate cancers. He has authored more than 300 peer-reviewed scientific publications and is involved in international oncology organisations, including ESMO, ASCO and AACR.

The company disclosed that Gustave Roussy will receive compensation for his participation. Innate Pharma also stated that his involvement does not constitute an endorsement of IPH4502 or a recommendation for its use.

The event will provide an opportunity for investors and other participants to hear the company’s explanation of the clinical data and ask questions about the programme’s development.

Innate Pharma’s wider oncology pipeline

IPH4502 is part of Innate Pharma’s broader portfolio of antibody-based cancer treatments. The company is developing ADC candidates alongside other immunotherapy programmes and has established collaborations with pharmaceutical companies including Sobi, Sanofi and AstraZeneca.

Its partnered programmes include lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, which is being evaluated in collaboration with AstraZeneca in non-small cell lung cancer.

In its November 5, 2026 business update, Innate Pharma said it expected the first patient to be dosed in the Phase 3 TELLOMAK-3 study of lacutamab in the first quarter of 2027. It also reported that the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab, was expected to deliver a high-level data readout in the first half of 2027.

The company reported cash, cash equivalents and financial assets of €96.8 million as of September 30, 2026, and said it anticipated its cash runway would extend until the end of the first quarter of 2028. This provides additional context for investors assessing the company’s ability to advance its clinical programmes, although the eventual cost and timing of future development remain subject to change.

Data presentation will be an important development milestone

The November 18 event represents an upcoming clinical data disclosure for Innate Pharma’s proprietary ADC programme. The findings could provide additional information about the safety profile and preliminary antitumour activity of IPH4502 after completion of dose escalation.

For the biotechnology industry, the programme is part of a wider effort to develop ADCs with different antibody targets, linkers and payloads. Companies are exploring these combinations to address treatment resistance and extend the use of targeted drug delivery across different cancer types.

The next stage for IPH4502 will depend on the clinical evidence presented and the company’s decisions on dose optimisation and further testing. The data will need to be assessed in the context of the number of patients studied, tumour types represented, duration of follow-up, safety findings and response measurements.

IPH4502 remains an investigational medicine and has not received marketing authorisation in the European Union or approval from the US Food and Drug Administration. Its safety and efficacy have not been established for commercial use, and the product is not available for commercial distribution.

The November 18 presentation will therefore be an important update on the programme’s early clinical progress, rather than a regulatory approval or confirmation of clinical benefit.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates